nasdaq question, page-10

Snork,
CCZ report indicates that UNI rollout will focus on new drugs rather than existing products. Perhaps due to the extensive process involved in getting the approval means its not worth it for old drugs, given their lesser patent life.

Whilst growth will be rapid, it's hard to judge exactly what the orders will be unless we know which drugs SA intends to package in the Unifill.

Point is, UNI's growth plan is perhaps representative of what they feel the demand will be for NEW drugs that are packaged as pre-fills, and to an extent, SA's current production is irrelevant.